Cyril H. Benes

31.0k total citations · 4 hit papers
123 papers, 10.9k citations indexed

About

Cyril H. Benes is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Cyril H. Benes has authored 123 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 92 papers in Molecular Biology, 49 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Cyril H. Benes's work include Cancer-related Molecular Pathways (14 papers), Cancer therapeutics and mechanisms (14 papers) and DNA Repair Mechanisms (13 papers). Cyril H. Benes is often cited by papers focused on Cancer-related Molecular Pathways (14 papers), Cancer therapeutics and mechanisms (14 papers) and DNA Repair Mechanisms (13 papers). Cyril H. Benes collaborates with scholars based in United States, United Kingdom and Germany. Cyril H. Benes's co-authors include Patricia Greninger, Ultan McDermott, Daniel A. Haber, Mathew J. Garnett, Jeffrey A. Engelman, Sridhar Ramaswamy, Lee Zou, Michael R. Stratton, Wanjuan Yang and Howard Lightfoot and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Cyril H. Benes

120 papers receiving 10.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

2012 2.6k citations Patricia Greninger, Daniel A. Haber et al. profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Cyril H. Benes, Lecia V. Sequist et al. profile →
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

2013 457 citations Alexandre Puissant, Stacey M. Frumm et al. Cancer Discovery profile →
Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

2015 376 citations Rachel Litman Flynn, Maya Jeitany et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cyril H. Benes United States	49	7.4k	4.0k	2.9k	2.5k	906	123	10.9k
Ultan McDermott United Kingdom	39	8.2k 1.1×	4.8k 1.2×	3.9k 1.3×	3.6k 1.5×	1.1k 1.2×	94	13.0k
Aik Choon Tan United States	56	6.8k 0.9×	4.5k 1.1×	2.0k 0.7×	2.8k 1.1×	430 0.5×	262	12.1k
Mathew J. Garnett United Kingdom	38	7.1k 1.0×	3.1k 0.8×	1.7k 0.6×	1.9k 0.8×	1.5k 1.6×	85	9.8k
Simon Forbes United Kingdom	21	7.6k 1.0×	2.8k 0.7×	2.2k 0.7×	4.0k 1.6×	798 0.9×	46	11.2k
Julien Sage United States	64	8.9k 1.2×	6.7k 1.6×	1.8k 0.6×	2.0k 0.8×	418 0.5×	150	14.2k
Michael A. Davies United States	57	7.4k 1.0×	6.9k 1.7×	2.6k 0.9×	1.9k 0.8×	661 0.7×	325	12.3k
Barry S. Taylor United States	46	5.5k 0.7×	3.3k 0.8×	2.7k 0.9×	3.0k 1.2×	370 0.4×	118	9.9k
Jeffrey R. Infante United States	63	6.9k 0.9×	9.0k 2.2×	3.5k 1.2×	2.5k 1.0×	491 0.5×	343	14.8k
Sarat Chandarlapaty United States	51	6.3k 0.9×	6.0k 1.5×	4.1k 1.4×	2.9k 1.2×	454 0.5×	205	12.6k
Kevin B. Kim United States	38	5.4k 0.7×	5.1k 1.3×	1.5k 0.5×	970 0.4×	854 0.9×	116	8.2k

Countries citing papers authored by Cyril H. Benes

Since Specialization

Citations

This map shows the geographic impact of Cyril H. Benes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyril H. Benes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyril H. Benes more than expected).

Fields of papers citing papers by Cyril H. Benes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyril H. Benes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyril H. Benes. The network helps show where Cyril H. Benes may publish in the future.

Co-authorship network of co-authors of Cyril H. Benes

This figure shows the co-authorship network connecting the top 25 collaborators of Cyril H. Benes. A scholar is included among the top collaborators of Cyril H. Benes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyril H. Benes. Cyril H. Benes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jacob, Sheeba, Jinyang Cai, Konstantinos V. Floros, et al.. (2022). Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models. PNAS Nexus. 1(5). pgac232–pgac232. 6 indexed citations

Krytska, Kateryna, Timothy L. Lochmann, Renata Sano, et al.. (2021). Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma. Molecular Cancer Therapeutics. 20(8). 1400–1411. 13 indexed citations

Heisey, Daniel A.R., Sheeba Jacob, Timothy L. Lochmann, et al.. (2021). Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Molecular Cancer Therapeutics. 20(10). 1868–1879. 11 indexed citations

Ben‐Hamo, Rotem, A. Berger, Nancy Gavert, et al.. (2020). Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nature Communications. 11(1). 3296–3296. 52 indexed citations

Lochmann, Timothy L., Konstantinos V. Floros, Mitra Naseri, et al.. (2017). Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clinical Cancer Research. 24(2). 360–369. 93 indexed citations

Buisson, Rémi, Michael S. Lawrence, Cyril H. Benes, & Lee Zou. (2017). APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. Cancer Research. 77(17). 4567–4578. 95 indexed citations

Ember, S.W., Que T. Lambert, Norbert Berndt, et al.. (2017). Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics. 16(6). 1054–1067. 41 indexed citations

Han, Jing, Lynnette Marcar, Joshua C. Black, et al.. (2017). Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin–EGFR Pathway. Cancer Research. 77(8). 2018–2028. 77 indexed citations

Liu, Yan, Yuyang Li, Xiaoen Wang, et al.. (2017). Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Research. 77(18). 5068–5076. 25 indexed citations

10.

Conery, Andrew R., Richard C. Centore, Archana Bommi‐Reddy, et al.. (2016). Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Research. 76(6). 1313–1319. 23 indexed citations

11.

Liu, Qi, Meng Wang, Jing Han, et al.. (2015). Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research. 13(4). 713–720. 29 indexed citations

12.

Rechem, Capucine Van, Joshua C. Black, Myriam Boukhali, et al.. (2015). Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis. Cancer Discovery. 5(3). 255–263. 51 indexed citations

13.

Flynn, Rachel Litman, Maya Jeitany, Hiroaki Wakimoto, et al.. (2015). Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 347(6219). 273–277. 376 indexed citations breakdown →

14.

Rechem, Capucine Van, Joshua C. Black, Patricia Greninger, et al.. (2015). A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors. Cancer Discovery. 5(3). 245–254. 22 indexed citations

15.

Alagesan, Brinda, Gianmarco Contino, Alexander R. Guimarães, et al.. (2014). Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research. 21(2). 396–404. 103 indexed citations

16.

Wang, Meng, Patricia Greninger, Anurag Singh, et al.. (2014). EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research. 74(10). 2825–2834. 55 indexed citations

17.

Heilmann, Andreas, Rushika M. Perera, Veronika Ecker, et al.. (2014). CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. Cancer Research. 74(14). 3947–3958. 90 indexed citations

18.

Emerling, Brooke M., Cyril H. Benes, George Poulogiannis, et al.. (2013). Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences. 110(9). 3483–3488. 49 indexed citations

19.

Puissant, Alexandre, Stacey M. Frumm, Gabriela Alexe, et al.. (2013). Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. Cancer Discovery. 3(3). 308–323. 457 indexed citations breakdown →

20.

Wang, Meng, Liliana Gheorghiu, Patricia Greninger, et al.. (2013). EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity. Cancer Research. 73(20). 6254–6263. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact